Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invega Trinza

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Searching for health

Janssen France’s Emmanuelle Quiles on finding ways to produce pharma innovations in a challenging environment

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

The world is our laboratory

Janssen's Thomas Stark on his company's approach to innovation, collaboration and research

- PMLiVE

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m

- PMLiVE

J&J buys firm seeking hepatitis B cure

Acquires Philadelphia-based Novira therapeutics

- PMLiVE

FDA approves Janssen’s Yondelis

Provides additional treatment option for softtissue sarcoma

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Sidestep into Crohn’s could help Stelara cope with new competition

Filing for new indication expected before year's end

- PMLiVE

J&J’s share buyback ‘doesn’t prevent acquisitions’

Comes as company reports 7.4% decrease in sales

- PMLiVE

FDA approves Alkermes’ long-acting Abilify

Aristada given the nod as injectable antipsychotic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links